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| INTRODUC TI ON
Thrombin generation has been used since the early 1950s. 1 At the start, whole blood or plasma was supplemented with triggers such as tissue factor or activator of the intrinsic pathway of the coagulation combined with calcium chloride to initiate coagulation. Thrombin generation was then evaluated by sampling the clotting mixture at regular intervals into a test tube containing fibrinogen. The clotting times were then recorded and the quantity of thrombin generated was derived from a calibration curve constructed with a known amount of thrombin. 2 Changes have been made and the test was improved by replacing fibrinogen by a chromogenic substrate specific for thrombin. This required the use of defibrinated plasma and a computer was used to calculate the parameters stemming from the thrombogram. 3 Finally, the chromogenic substrate was replaced by a fluorogenic substrate, which permits the measurement of thrombin in samples that were not defibrinated because fluorescence is not hampered by the turbidity generated during the clotting process. These improvements have laid the groundwork for what is now known as calibrated automated thrombogram (CAT). 4 Currently, different solutions are available on the market to measure thrombin generation. 5 These are the Innovance ETP (Siemens Healthcare), the only one still based on the cleavage of a chromogenic substrate as readout, the Technothrombin TGA (Technoclone) and the Thrombinoscope CAT (Diagnostica Stago). These last two both use a fluorogenic substrate 5 ; however, some limitations have been highlighted, such as the lack of established standardization of the methods and reagents, and missing quality controls. In addition, batch-to-batch variations have been reported which further hampers study-tostudy comparisons. [6] [7] [8] As a consequence, efforts have been made since the past decade to reduce the interlaboratory variation, such as the use of a reference plasma to normalize the results. 9 Without the use of this reference plasma, coefficient of variation (CVs) for the most global parameter of CAT (i.e., the endogenous thrombin potential [ETP]), were often higher than 15%. This also raised the question of different local practices which may explain, in part, this high CV. 10 Even if this strategy appeared to efficiently reduce the interlaboratory variation and showed the potential benefit of results normalization, improvements are still needed to ensure a proper standardization of the method and its implementation in the routine daily care of patient. Namely, it has been reported that standardization of the tested conditions (e.g., control of the temperature throughout the process, preheating of the sample and the reagents, collection tube or centrifugation) may significantly affect the CAT parameters. [8] [9] [10] [11] Thus, for its implementation in routine daily care, the CAT system had to move to a next generation of analyzers able to perform the analyses individually and not by batch, with strict control of all variables to ensure maximal reproducibility.
The newly developed ST Genesia is a fully automated system intended to measure thrombin generation. It provides capacity to continuously load patients' samples for unitary testing. This new system has been designed to offer enhanced reproducibility compared with CAT and also to provide traceability and standardization, two criteria necessary to fulfill the requirements of an in vitro diagnostics format and to enter the clinical laboratory.
Numerous studies showed that thrombin generation measurement is sensitive enough to detect the presence of anticoagulants in inter-experiments variability. Stability revealed that plasma samples are stable for at least 11 months at −70°C or lower, except for those containing low molecular weight heparins which have to be tested within 6 months. Freezing had no effect on the majority of thrombin generation parameters except on time to peak.
Conclusions:
Our results suggest an easy implementation of thrombin generation with the use of ST Genesia in the routine laboratory. This will facilitate the design of multicentric studies and enable the establishment of reliable and evidence-based thresholds, which may improve the management of patients treated with anticoagulants.
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anticoagulants, blood coagulation tests, clinical laboratory techniques, normal range, reproducibility Essentials • Thrombin generation testing is widely used to provide information on the coagulation phenotype of patients.
• Some limitations have been highlighted such as the lack of established standardization.
• This is the first study reporting precision results of the ST Genesia.
• Normal range of the STG-DrugScreen application has been assessed in healthy subjects.
• The ST Genesia may facilitate the implementation of thrombin generation in the routine laboratory.
patients' plasma and to evaluate the intensity of the treatment [12] [13] [14] [15] [16] [17] [18] [19] therefore, Diagnostica Stago aimed at developing a kit for the assessment of thrombin generation in anticoagulated patients, the STG-DrugScreen. The first aim of this study was to determine the precision of the device with this kit and the utility of the normalization of the results. Second, this study aimed at assessing the stability of the plasma samples over time after freezing as well as defining the normal range of the STG-DrugScreen application in a normal healthy population.
| MATERIAL S AND ME THODS
The study intends to evaluate the precision performance of the device under final user setting and investigate the stability of thrombin generation results on samples stored at −70°C or lower. The study was in accordance with the Declaration of Helsinki and has been approved by the Ethical Committee of the CHU UCL Namur, Yvoir, Namur, Belgium. The study took place from June 2016 to September 2017 at the CHU UCL Namur, Yvoir, Belgium.
| Plasma collection of patients' and healthy donors' samples
Blood was taken by venipuncture in the antecubital vein and collected into 0.109 M sodium citrate (9:1 v/v) tubes (Vacuette, Greiner, Austria) without corn trypsin inhibitor using a 21-gauge needle (Terumo). The first tube was always discarded and the first centrifugation was performed within 30 minutes. The platelet-poor plasma (PPP) was obtained from the supernatant fraction of blood tubes after a double centrifugation for 15 minutes at 1500 × g at room temperature. The centrifuge brake was set to the minimum position at the end of the process. The residual platelet count was assessed every week to ensure the centrifugation procedure provides plasma with a platelet count <10,000 platelets/μL. Immediately after centrifugation, PPP was aliquoted by 600 μL (n = 12 for the stability study, n = 4 for the normal range definition study) and frozen at ≤−70°C without any delay (except for one aliquot tested fresh in the stability study). Frozen PPP samples were thawed, heated to 37°C for 2-3 minutes and mixed gently just before the experiment. All tests were performed within 4 hours after thawing.
| Normal and targeted population and samples
Six healthy individuals and 23 samples from patients treated with an anticoagulant have been included in the stability study (apixaban n = 4; dabigatran n = 3; low-molecular-weight heparins [LMWH] n = 5; rivaroxaban n = 5; vitamin K antagonists [VKA] n = 6). For patients on apixaban, dabigatran, and rivaroxaban, plasma had to be taken at peak (i.e., between 30 minutes and 4 hours after drug intake) to obtain the highest effect on thrombin generation. For patients under LMWH, the blood had to be taken between 1 and 6 hours after the administration while for patients under VKA, the targeted international normalized ratio (INR) was between 2 and 3.
For the definition of the normal range, 42 healthy individuals (mean age = 20 ± 3 years; min-max range = 18-32 years), not taking any antithrombotic therapy and not having any hemostasis disorders were included in the study.
| Assessment of thrombin generation
Thrombin generation has been assessed on an ST Genesia analyzer using the STG-DrugScreen application. More information about the analyzer, its methodology and the reagents are provided in the supplementary material. Low DS]) and the reference plasma (i.e., the STG-RefPlasma DS) over this period. Both the absolute and normalized results of the lag time, time-to-peak, ETP, and peak height were extracted, and the mean, standard deviation and CV computed from those results.
| Assessment of anticoagulant activity with specific tests

| Determination of the precision of the ST Genesia in its STG-DrugScreen application
| Determination of the stability after freezing of the plasma samples for thrombin generation measurement
Fresh plasma from the six healthy individuals, six patients on VKA, five on LMWH, four on apixaban, three on dabigatran, and five on rivaroxaban were tested at different time points to assess the stability of the different thrombin generation parameters over time. Testing was performed on follows.
• On a fresh sample (the day of plasma collection after centrifugation)
• At day 1, month 1, month 3, month 6, month 9, month 10, and month 11 (for healthy individuals only) after freezing at −70°C or lower. The maximal deviation tolerated was 7 days except for day 1 for which no deviation was tolerated.
The stability of thrombin generation results once the plasma has been frozen at −70°C or lower was assessed on the lag time, timeto-peak, ETP, and peak height using the method of the rejection limit (RL). This method aims to establish the length of time during which the measurement of the thrombin generation is acceptable, when carefully following laboratory's established sample handling and storage conditions. Briefly, the percent bias (or the %RL) was over time. For each parameter, the 100% RL is defined based on the maximal allowable error (MAE). To take into account method precision, reagents aging, and sample aging, the MAE was set at 20% for the ETP and at 18% for the lag time, time-to-peak, and the peak height. The RL is also adjusted according to the value of the intercept of the linear regression with the y axis. The maximal sample stability is defined as the intercept of the 95% confidence interval (CI) of the linear regression with the adjusted rejection limit. If there is no interception, the maximal duration limit is de- F I G U R E 1 Stability of the different thrombin generation parameters. The 100% rejection limit (RL) has been defined as the maximal allowable error (MAE). For the endogenous thrombin potential (ETP), the MAE was 20% and for the lag time, time to peak, and the peak height; the MAE was 18% based on the data from the precision study. The Y-intercept was used to determine the adjusted RL (upper adjusted RL = 100 + Y-intercept -lower adjusted RL = −100 + Y-intercept). The 95% confidence interval of the linear regression (blue hashed zone) do not cross the adjusted RL, which means that the samples are stable over the analyzed period (i.e., 11 months for healthy subject and 10 months for anticoagulated patients) The impact of freezing was assessed comparing the results of each sample at day 0 (i.e., fresh sample) to the results obtained at day 1. To provide evidence of the normal distribution of the results, a Shapiro-Wilk test using an α-risk of 5% (two-sided CI) has been performed. If the population had not a normal distribution, then the paired results were compared using a Wilcoxon matched ranksigned test. If the distribution was normal, then the means were compared with a t test for paired samples. In both cases, a P value below 5% leads to the conclusion of significant impact of freezing on results.
| RE SULTS
| Thrombin generation values of the reference plasma and controls and precision of the ST-Genesia
The within-batch variability was always below the between-batches relative differences, except for the normalized ETP of the STG-QualiTest Low DS ( Table 1 ). The within-batch variability was always below 6%. All results are summarized in Table 1 .
| Impact on freezing on thrombin generation parameters
On the total cohort (n = 29 samples), Shapiro-Wilk normality test showed normal distribution for the lag time and the ETP parameters, whereas the normality failed for the peak height and the time to peak. This means that, according to the statistical analysis plan, a t test for paired samples was used for the lag time and the ETP, whereas a Wilcoxon matched rank-signed test was used for the peak height and the time-to-peak. Because of a small sample size, the Wilcoxon matched rank-signed test was used when the results were stratified by treatment ( Table 2) .
Wilcoxon matched rank-signed test revealed no significant difference between the two conditions on lag time, peak height, and ETP, whereas the time-to-peak was impaired (mean of difference = −0.15 minutes). When results are analyzed by treatment, there is no significant difference between fresh and frozen plasma ( Table 2 ).
| Stability of the plasma samples once conserved at −70°C or below
For the lag time, the adjusted RLs are −100% to 100%, the slope of the linear regression was equal to 0.414 (95% CI, −1.358 to 2.185).
The 95% CI of the linear regression did not cross the adjusted RLs ( Figure 1 ) and the maximal storage duration was defined as the latest point assessed in this study (i.e., 11 months for healthy volunteers and 10 months for anticoagulated patients). Stratification by treatment did not provide different results (Table 3 ). For the time to peak, the adjusted RLs were −104% to 96%, the slope of linear regression was equal to −1.596 (95% CI, −3.113 to −0.078; significant nonzero). The 95% CI of the linear regression did not cross the adjusted RLs (Figure 1 ) and the maximal storage duration for this parameter was also defined at the latest point assessed in this study (i.e., 11 months). Again, stratification by treatment did not provide different results (Table 3) . For the peak height, the adjusted RLs were −110% to 90%, the slope of linear regression was equal to 3.749 (95% CI, −1.675 to 5.822). The 95% CI of the linear regression did not cross the adjusted RLs ( Figure 1 ) and the maximal storage duration for this parameter was also defined at the latest point assessed in this study (i.e., 11 months). Stratification by treatment revealed that the peak height is only stable for 6 months in samples from patients with LMWH (Table 3 and Figure 2 ). For the ETP, the adjusted RLs were −104% to 96%, the slope of linear regression was equal to 2.453 (95% CI, 0.886-4.019). The 95%CI of the linear regression did not cross the adjusted RLs (Figure 1 ) and the maximal storage duration for this parameter was defined at the latest point assessed in this study (i.e., 11 months). Stratification by treatment did not provide different results (Table 3 ).
| Thrombin generation in the normal and targeted population
The reference values obtained in the healthy population revealed thrombin generation values close to the value of the reference plasma (Table 4 ). Screening coagulation testing, namely the PT and aPTT, were normal in all healthy individuals (PT: mean = 13.7 ± 0.7 seconds; min-max range = 11.9-15.10 seconds; and aPTT: mean = 31.5 ± 2.5 seconds; min-max range = 27.1-36.7 seconds). For apixaban, measured drug plasma levels through anti-Xa method were between 158 and 370 ng/ mL, the normalized thrombin generation parameters were all affected by the treatment (Table 5 ). No clear correlation could be drawn from this small population (n = 4) between thrombin generation parameters and the plasma level. For dabigatran, peak plasma levels were between 51 and 187 ng/mL, the normalized lag time and time to peak were affected in all subjects, whereas the ETP and the peak height were not different from the healthy subjects at the lowest concentration observed (i.e., 51 ng/mL) ( Table 5 ). For LMWH, the peak anti-Xa effect were between 0.35 IU/mL and 1.37 IU/mL. All thrombin generation parameters were affected. In the patient with the highest exposure (i.e., 1.37 IU/mL), the peak height and the ETP were highly affected (8% and 14% the value of the reference plasma, respectively) ( Table 5 ). For rivaroxaban, the peak plasma concentrations were between 197 and 300 ng/mL. The most affected thrombin generation parameters were the peak height and the time to peak ( Table 5 ). In patient 1, the rivaroxaban concentration was 229 ng/mL, the peak height dropped to 37% with significant prolongation of the time to peak but the ETP was not affected (i.e., 101% the value of the reference plasma). In patients treated with VKA, the INR varied between 1.86 and 3.31. The peak and the ETP were the most influenced thrombin generation parameters while lag time and time to peak were less influenced ( Table 5) . Note: Results are presented as CV expressed in percentage. For the 2 levels of controls, results are presented as absolute or normalized (against STG -RefPLasma DS). The use of a reference plasma titrated by a manufacturer reduces the interbatch variation. Difference in % represents the relative difference between the two batches of reagents and controls for each TGT parameter.
CV, coefficient of variation; SD, standard deviation; TGT, thrombin generation test.
TA B L E 1 (Continues)
| D ISCUSS I ON
This is the first study evaluating the performances of the ST Genesia, a benchtop analyzer for thrombin generation in the routine setting.
This instrument aims at introducing thrombin generation testing in the routine laboratory. Indeed, to date, the CAT system is probably one of the most used thrombin generation technique in research laboratories but the use of a microtiter plate, the manual placing of the sample and the reagents into the wells, added to the lack of standardized procedure and reagents have prevented its introduction into When the regression slope is statistically significant (P ≤ 0.05) from zero, and the one-sided 95% confidence limit of the regression line intersects the adjusted rejection limit before reaching T MAX , the maximum storage time is determined as this intersection.
TA B L E 3 (Continues)
TA B L E 5 Thrombin generation results at T0 of all patients and healthy donors included in the stability study Patient no.
Lag time absolute
Peak height absolute the routine practice. 2 By providing a complete kit of reagent and controls, the STG-DrugScreen application of the ST Genesia simplifies the evaluation of the thrombin generation in patients treated with anticoagulants in the routine laboratory. This is made possible by the standardized and validated methodology of the ST Genesia.
The ST Genesia is derived from the CAT principle, but is not strictly equivalent. Yet, as already shown by others, 20 there is a direct correlation between the two systems under comparable triggering conditions. This study is not intended to provide the clinical performance of the STG-DrugScreen application to predict any clinical events, but to provide the analytical performance of the system in the routine setting and to evaluate the stability of the samples once conserved at −70°C or below.
The precision of the ST Genesia has been evaluated using the data from the daily calibration and the value of the two levels of control and reference plasma (i.e., the STG-QualiTest Low DS and STG-QualiTest Norm DS and STG-RefPlasma DS, respectively) over a 15-month period. Two batches of reagents were provided by the manufacturer during the course of this study. Main results revealed that the coefficient of variation of the different parameters were always <10% and for the majority of these results the CV was even <5% ( Table 1) . As previously reported, 10 this study also demonstrates that the use of a reference plasma reduced the interexperiment variability. Regarding the stability of the samples, our results demonstrate that freezing has no impact on most thrombin generation parameters except the time to peak, especially in samples containing apixaban, dabigatran, or rivaroxaban. Our data suggest that the plasma, once frozen, is stable during at least 11 months, except for LMWH samples, for which the maximal duration storage is 6 months.
As mentioned, this study has limitations. First, this is a monocentric study and, thus, the interlaboratory performance of the ST Genesia has not been assessed. Second, results of external quality assurance program have not been included in this validation because the current thrombin generation EQA program is not designed for thrombin generation assessment of anticoagulant treatment 21 and thus the high tissue factor activity of the STG-DrugScreen trigger may not be comparable to that of the other reagents and methodologies. Finally, the study was not powered to drive any conclusions regarding the effect of anticoagulants on thrombin generation because only peak plasma samples were collected for this part of the study. Only trends can be drawn on the overall effect of the different anticoagulant agents; further work is necessary to define the minimal concentration of anticoagulants that would yield results outside the reference range.
| Reference plasma
Many previous publications recommended the use of a reference plasma to reduce the interlaboratory variability. 6, 7, 9, 10 The choice of providing a reference plasma within the STG-DrugScreen kit agrees with the literature because it has been reported that the use of local plasma (i.e., a reference plasma performed at the laboratory facilities) were generally unable to improve the interlaboratory variability or the CV is even worsen after normalization. 6, 8, 10 The choice of a commercially available and certificated plasma is therefore more appropriate than using local plasma. On the other hand, it has been reported a certain heterogeneity between the different reference plasma which may impede the benefit of the use of such reference plasma. 6 Therefore, the best approach would be to use a reference plasma specifically dedicated for the application. This strategy improves the between-batch variation. In this study, we report relative differences between batches from 0% to 24% when results are not normalized ( Table 1 ; see results of the controls).
Once results are normalized most of the parameters show better inter-batch CVs (except for the peak height with the STG-QualiTest Low DS), demonstrating the efficiency of this approach. The choice of a freeze-dried plasma can be challenged because it has been reported that these plasmas have higher thrombin generation capacity than frozen plasma from multiple preanalytical reasons. 6, 22 In any case, the conditions in which these reference plasmas are produced are probably far from the best recommendations of blood sample collection for thrombin generation testing because these reference plasmas have to be produced on a large scale. Thus, one solution may be to assess the response of the commercial reference plasma to a smaller pool of plasma from healthy donors collected in ideal conditions and then to apply a correction factor to the commercial plasma to compensate for these differences. In the package insert of the STG-DrugScreen kit, an assay value of the reference plasma is provided by the manufacturer to correct the reference plasma activity. The results of this study demonstrate that this approach is efficient since our healthy subjects, collected in ideal conditions for this application, were close to 100% or a ratio of 1 depending on the parameter (Table 5 ). In addition, the difference between the two batches of the STG-RefPlasma DS was ≤5% for all thrombin generation parameters demonstrating that the use of a correction factor specific to each batch of reagent and reference plasma is useful to reduce the batch-to-batch variation ( Table 1 ).
| Quality controls
It has been reported that internal quality control is essential to produce consistent results for thrombin generation 23 however, in the era of thrombin generation, the confusion between internal quality control and a reference is often made. Namely, most studies have proposed to normalize the results according to a reference plasma, 6, 7, 9, 10, 23 which is not the same as true control plasma. To comply with local legislation, regulations, guidelines, or standards issued by relevant bodies, at least two levels of controls are recommended.
Thus, this is of upmost importance for thrombin generation to propose such different level of controls to allow the implementation of thrombin generation into routine testing. This will ensure the technique is under control for both normal and abnormal sample analysis.
Over our series of 97 measurements of the reference plasma and the quality controls, we demonstrate that the CVs of the normalized results were always below 10% and for the majority of the parameters were even below 5%. These interassay precision results are in line with the intra-and interassay reproducibility data provided by the manufacturer in the insert-sheet of the STG-DrugScreen kit (Table S2 ). All of these data demonstrate that the STG-DrugScreen performed on the ST Genesia is a precise thrombin generation application, which will allow thrombin generation to be performed routinely to assess patients treated with anticoagulants. All the requirements are now met to implement this technique in the routine laboratory. Freezing has no effect on the majority of the thrombin generation parameters using the STG-DrugScreen application, except for time to peak ( 
| Impact of freezing and stability of the samples
| Normal range definition
In this study, 42 samples from healthy donors were tested to provide grounds for the definition of a normal for the STG-DrugScreen application on the ST-Genesia. All these samples were normal according to PT and aPTT screening. The small correction between absolute and normal value is certainly because all 42 samples were tested on the same day with the first batch of reagents (i.e., batch 201797). For all the parameters, the interindividual variation was always below 20% and was below 10% for the lag time and the time-to-peak. When comparing with the results obtained in patients treated with an anticoagulant, the 10th-90th percentile range ( Table 4 ) could serve as a basis for the classification of normal and abnormal plasma. It could be proposed that samples below the 10th percentile (for peak height and ETP) and above the 90th percentile (for lag time and time to peak) may represent samples in which anticoagulant therapy is suspected. However, further studies in larger cohorts of patients taking anticoagulants are needed before adopting this assumption.
| Usefulness of thrombin generation to assess anticoagulated patients
Tailoring drug dosages to fit the needs of individual patients could be helpful to make old and new drugs more effective and safer. 2 Preliminary observations showed that thrombin generation testing is affected by all anticoagulant drugs and therefore it could be the candidate assay. 18, 19, [28] [29] [30] [31] The test has been found to be very sensitive to all kind of anticoagulants [13] [14] [15] [16] 18, 32, 33 and may best represent the interindividual response than just exploring plasma drug concentrations. 28 In addition to considering the interindividual response to an antithrombotic drug, thrombin generation testing is also able to explore in more detail the effect of anticoagulants on the coagulation process. Namely, depending the type of drug, our results confirmed that the fingerprint of the thrombin generation differs, revealing their different pharmacodynamics (Table 5 ). 17, 18, 32, 34 This is of particular importance because bleeding or thrombosis have been reported within the "on-therapy" range, demonstrating that the drug level alone may not be sufficient to identify those who are more at risk. 35 However, further investigation on patients who bleed or who have recurrent thrombosis while on a fixed dose of anticoagulants is needed to show the benefit of thrombin generation and provide cutoffs for bleeding and thrombotic complications. Thrombin generation has also been reported as an informative tool to document on antidote administration in polytrauma models with direct implication for patient care. 36 This is particularly important because it may help in adjusting the dose of prothrombin complex concentrate to administer. 37 The ST Genesia will provide a step forward to this aim in allowing thrombin generation to be done routinely with reduced interexperiments and interlaboratory variations. In this way, it will be easier to recruit patients, design multicenter studies, and provide data for the establishment of reliable and evidence-based thresholds. 
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